Multiple studies at the 65th American Society of Hematology Annual Meeting 2023 have the potential to change the treatment paradigm for first-line treatment of multiple myeloma.
It’s not every day you see a small drug company’s presentations get picked for both the plenary session and the late-breaker session at a conference, but Syndax Pharmaceuticals Inc. managed to do just that at the 65th American Society of Hematology Annual Meeting 2023 – with a little help from a friend.
Degrader-antibody conjugates (DACs) are at the heart of the new deal between C4 Therapeutics Inc. and Merck & Co. Inc. C4 will get $10 million up front, milestones that could total $600 million and about $2.5 billion across the entire collaboration.
South Korean pharmaceuticals Celltrion Inc. and Cyron Therapeutics Co. Ltd. are teaming up to discover and develop bispecific and trispecific antibodies, collectively called polyspecific antibodies, under the ₩1.158 trillion (US$882.38 million) joint research agreement inked on Dec. 6. Under the terms, privately held Daegu-based Cyron will discover and develop at least three polyspecific antibodies for blood and solid cancers pre-selected by Incheon-based Celltrion via Cryon’s CD-3 targeting T-cell engager platform that helps engage T cells to attack cancer cells.
Prescient Therapeutics Pty Ltd.’s PTX-100 met primary safety endpoints and showed preliminary efficacy in a phase Ib trial in patients with relapsed and refractory T-cell lymphomas that exceeded the standard of care, and the company hopes to advance to a phase II registrational study in 2024, Prescient CEO Steven Yatomi-Clarke told BioWorld.
Akadeum Life Sciences Inc. hopes to transform the world of cell therapy with the Alerion cell separation system, which it plans to launch in the next 12 months, Brandon McNaughton, founder and CEO of Akadeum, told BioWorld. The instrument will provide a closed system for separating T cells from a leukopak using Akadeum’s buoyancy-activated cell-sorting (BACS) microbubble technology.
Systimmune Inc. and Bristol Myers Squibb Co. have joined hands in a co-development deal for bispecific antibody drug conjugate (ADC) BL-B01D1 in a deal worth up to $8.4 billion. The deal falls on the heels of BMS acquiring Mirati Therapeutics in October 2023 for $4.8 billion to add to its oncology pipeline.
Systimmune Inc. and Bristol Myers Squibb Co. have joined hands in a co-development deal for bispecific antibody drug conjugate (ADC) BL-B01D1 in a deal worth up to $8.4 billion. The deal falls on the heels of BMS acquiring Mirati Therapeutics in October 2023 for $4.8 billion to add to its oncology pipeline.
Tarapeutics Science Inc. has divulged tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, fibrosis, immunological, eye and cardiovascular disorders.
Researchers at Admare Bioinnovations, Lifearc and Provincial Health Services Authority (PHSA) have disclosed DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.
RSS
